Call us : 855-228-7355

Investor Relations

Agent Benefits 4

* News Alert

Novus’s Positive Financial Performance and Market Position Highlighted in 1Q 2025 Report

A New Era of Benefits: Integrating Cannabis into Prescription Plans via D2C Platform

Since 2015, Novus Acquisition & Development Corporation (NDEV), doing business as Novus Cannabis MedPlan®, has been a pioneering health insurance carrier that integrates THC and CBD cannabis into health plans for both medical and recreational cannabis consumers. With a national network of agents, brokers, and dispensaries, NDEV generates revenue through insurance premiums and provides policyholders access to cannabis and traditional medications through its prescription and cannabis distribution online platform. NDEV’s sustainability is based on its receivable-based business model and has attracted interest from major carriers and InsurTech platforms for plan integration.

Potential investors should consult with their investment professional regarding Novus trading below its intrinsic value. This situation can be evaluated using the Benefit Monetization Ratio, which supports Novus’s long-term vision, sustainable business model, and potential for future growth.

Cap Structure
As of  March 31, 2025
Authorized Shares:200 million
Outstanding Shares:126,803,624
Float:30,948,730
Par Value:$0.001
Restricted Shares:86,989,251
Due Diligence Links 
As of  March 31, 2025
Quote:Click Here
Filings:Click Here
Pitch Deck:Click Here
Investment Highlights Video:Click Here
  

Footnotes:

  • Leak Out Vendor Shares: Third-party vendors with treasury-issued stock must sell their shares gradually based on 15% of the average daily trading volume over the past 30 days.
  • Debt Transparency: Frank Labrozzi, the CEO, is owed $163,425. He has no plans to exercise the call provision, and this debt instrument has no equity conversion provision.
  • Insider Sales: No insider selling common stock for three years
Disclaimer and Forward-Looking Statement Click Here. Always seek advice from a licensed financial professional before making any investments. 

Integration Reimbursement of Cannabis Plans

  • Employer-Centric Customization: The platform allows companies to tailor health benefits, including medical cannabis, to align with their HR policies and values.
  • Positions Novus as a compliant, tax-advantaged solution for medical cannabis reimbursement with Health Savings Accounts and Health Reimbursement Accounts.
  • Cannabis policyholders can use pre-tax dollars for premiums, enhancing affordability and accessibility.

 

Direct-to-Consumer Platform Launch:

                                                (See Platform Video Here)
  • Introduced a Cannabis RX platform designed to:
    • Provide direct sales to medical and recreational policyholders.
    • Offer pre-negotiated discounts to enhance affordability.
    • Integrate a cannabis inclusive percrition drug plan
    • Nationwide Network of Licensed Dispensaries Across the U.S.
    • Combines cannabis and traditional healthcare benefits in a single plan.
    • Positioned as a disruptive distribution solution in the medical and recreational cannabis industry.

                                   Download Rx Platform App Here

 

Market Expansion Efforts:

The platform targeted medical users, unregistered consumers from the illicit market, and recreational users.

  • Created affordable wellness programs with customized insurance benefits.
  • Partnering with dispensaries, cannabis brands, and insurance brokers nationwide to offer Novus MedPlan, which provides comprehensive coverage solutions for diverse needs.
  • The untapped employer market captures market share by targeting companies adjusting HR policies on cannabis in the workplace.




Unaffected by the Complications of Federal Cannabis Compliance.

Novus is not impacted by the SAFE Banking Act or the process of rescheduling cannabis. As a non-plant-touching company, we encounter fewer legal and regulatory challenges. Insurance providers operate on a state-by-state basis, and since federal cannabis laws do not apply directly to us, we can operate across state and national borders with fewer restrictions.

Undervalued Analysis

Explore the Growth Potential of Novus: Novus’s management believes the current stock price presents a possible investment opportunity. This perspective is based on our internal Net Asset Value (NAV) calculation per Share. This is how insurance companies are valued.

Net Asset Value per Share Calculation: To determine the NAV per Share, we first calculated the company’s total Net Asset Value. This figure represents the difference between our total assets and liabilities, clearly showing the company’s underlying intrinsic value. Subsequently, we divided this Net Asset Value by the total number of Shares Issued and Outstanding. This calculation yields the Net Asset Value attributable to each share of Novus stock.

Industry Valuation Multiple: To arrive at our view of potential investment value, we applied an industry-standard valuation multiple of approximately 20 to our calculated Net Asset Value per Share. This multiple is derived from the average trading multiples observed for publicly traded companies within our peer group and broader industry. Using an industry-standard multiple allows for a comparative assessment of Novus’s potential value relative to its competitors.

Alignment with Comparable Valuations: Applying this multiple of approximately 20 is appropriate as it aligns with the prevailing valuations observed for comparable companies within our industry. These companies often share similar business models, growth prospects, and risk profiles, making their valuation metrics potentially relevant benchmarks for Novus.

Reflection of Unique Asset Base: This valuation approach may appropriately reflect Novus’s unique and valuable asset base. Our assets, which contribute significantly to our overall Net Asset Value, possess distinct characteristics and potential that are not fully reflected in the current market price.

Further Information: For a more detailed understanding of our Net Asset Value calculation, the specific components of our asset base, the selection criteria for our industry comparables, and the rationale behind the chosen valuation multiple, we encourage interested parties to visit the Investor Relations section of our website, the materials available on this page provide comprehensive information and transparency regarding our valuation methodology and investment rationale.

Important Disclaimer: Investors must understand that the projections and valuation assessments presented here represent Novus’s management team’s current views and analysis. These are based on information available to us at this time and are subject to various assumptions, market conditions, and inherent uncertainties. Therefore, we strongly advise you to carefully review all available information, conduct your own independent due diligence, and consult with a qualified financial professional before making any investment decisions. Investment in securities involves risk, and past performance is not indicative of future results. Your financial advisor can help you assess your risk tolerance and investment objectives and determine if an investment in Novus suits your portfolio.

Contact Us

* Indicates Required Field

855-228-7355

We are available Monday - Friday 9:00 am - 5:00 pm (EST) Email: info@getnovusnow.com

  • follow us on